Part, Chapter, Paragraph
1 II, 5. 2. 6| 130/80, if feasible, in diabetic or patients with established
2 II, 5. 4. 1| Microvascular complications (diabetic retinopathy, nephropathy
3 II, 5. 4. 1| representing the majority of the diabetic population:~ ~·Type 1 diabetes
4 II, 5. 4. 1| percentage of about 10% of the diabetic population is affected by
5 II, 5. 4. 1| almost 80% of the total diabetic population resides in developing
6 II, 5. 4. 2| active partnership with diabetic citizens, their families,
7 II, 5. 4. 2| linkage with other databases: diabetic patients may be identified
8 II, 5. 4. 2| pharmaceutical use made by diabetic patients.~A limitation of
9 II, 5. 4. 2| incidence of blindness due to diabetic retinopathy/total annual
10 II, 5. 4. 2| incidence of blindness due to diabetic retinopathy is defined as
11 II, 5. 4. 2| blindness in one year due to diabetic retinopathy/total number
12 II, 5. 4. 2| 100,000 individuals in the diabetic population in one year.~
13 II, 5. 4. 2| transplantation per 100.000 diabetic population is defined as
14 II, 5. 4. 2| 100,000 individuals in the diabetic population.~Mortality is
15 II, 5. 4. 2| exception of diabetes coma, most diabetic patients die from macrovascular
16 II, 5. 4. 2| complications~ ~Percent of diabetic subjects and a HbA1c tested
17 II, 5. 4. 2| 12 months~16~Percent of diabetic subjects and a HbA1c tested,
18 II, 5. 4. 2| HbA1c>7.5%~14~Percent of diabetic subjects with a lipid profile
19 II, 5. 4. 2| 12 months~14~Percent of diabetic subjects tested in the last
20 II, 5. 4. 2| cholesterol>5 mmol/l~14~Percent of diabetic subjects tested in the last
21 II, 5. 4. 2| 3 mmol/l)~13~Percent of diabetic subjects tested in the last
22 II, 5. 4. 2| 0 mmol/l)~11~Percent of diabetic subjects tested in the last
23 II, 5. 4. 2| 0 mmol/l)~12~Percent of diabetic subjects tested for microalbuminuria
24 II, 5. 4. 2| 12 months~12~Percent of diabetic subjects with a tested microalbuminuria
25 II, 5. 4. 2| abnormal level~11~Percent of diabetic subjects with a tested blood
26 II, 5. 4. 2| months~14~Percent of of diabetic subjects with a tested blood
27 II, 5. 4. 2| value >140/90~10~Percent of diabetic subjects who are smoking~
28 II, 5. 4. 2| are smoking~14~Percent of diabetic subjects and a BMI 25 kg/
29 II, 5. 4. 2| complications~ ~Percent of diabetic subjects with fundus inspection
30 II, 5. 4. 2| 12 months~11~Percent of diabetic subjects tested in the last
31 II, 5. 4. 2| last 12 months~6~Percent of diabetic subjects who received laser
32 II, 5. 4. 2| retinopathy~1~Percent of diabetic subjects tested serum creatinine
33 II, 5. 4. 2| 12 months~13~Percent of diabetic subjects with ESRF serum
34 II, 5. 4. 2| traumatic but medical) in diabetic patients /100,000 general
35 II, 5. 4. 2| Annual incidence of stroke in diabetic patients /100,000 general
36 II, 5. 4. 2| myocardial infarction in diabetic patients/100,000 general
37 II, 5. 4. 2| percentage of the total diabetic population that had their
38 II, 5. 4. 2| the percentage of total diabetic population with HbA1c tested
39 II, 5. 4. 2| parameter for lipids in the diabetic population. It is measured
40 II, 5. 4. 2| the percentage of total diabetic population that had their
41 II, 5. 4. 2| measured as the percentage of diabetic population with their total
42 II, 5. 4. 2| by the percentage of the diabetic population that had their
43 II, 5. 4. 2| as the percentage of the diabetic population with LDL-cholesterol
44 II, 5. 4. 2| by the percentage of the diabetic population that had their
45 II, 5. 4. 2| as the percentage of the diabetic population with their HDL-cholesterol
46 II, 5. 4. 2| parameter for lipids in the diabetic population. It is measured
47 II, 5. 4. 2| the percentage of total diabetic population that had their
48 II, 5. 4. 2| measured as the percentage of diabetic population with their total
49 II, 5. 4. 2| the percentage of total diabetic population that had microalbuminuria
50 II, 5. 4. 2| measured as the percentage of diabetic population with microalbuminuria/
51 II, 5. 4. 2| through the percentage of diabetic subjects that had their
52 II, 5. 4. 2| measured as the percentage of diabetic subjects that had their
53 II, 5. 4. 2| percentage of smokers in the diabetic population.~Levels of BMI
54 II, 5. 4. 2| measured as the percentage of diabetic population that had their
55 II, 5. 4. 2| measured by the percentage of diabetic population that had their
56 II, 5. 4. 2| defined as the percentage of diabetic population that had their
57 II, 5. 4. 2| defined as the percentage of diabetic population that had their
58 II, 5. 4. 2| defined as the percentage of diabetic population that had their
59 II, 5. 4. 2| measured as the percentage of diabetic population with creatinine
60 II, 5. 4. 2| 100,000 individuals in the diabetic population in one year.
61 II, 5. 4. 2| 100,000 individuals in the diabetic population in one year.~
62 II, 5. 4. 2| 100,000 individuals in the diabetic population in one year.~ ~
63 II, 5. 4. 3| incidence of blindness due to diabetic retinopathy. EUCID found
64 II, 5. 4. 3| transplantation per 100.000 diabetic population. Across 11 countries,
65 II, 5. 4. 3| defined as the percentage of diabetic population that had their
66 II, 5. 4. 7| clinical setting, where the diabetic patient is met and where
67 II, 5. 7. 3| higher US incidence rate of diabetic ESRD.~ ~Table 5.7.3. Incidence
68 II, 5. 7. 3| the incidence of RRT for diabetic and hypertensive ESRD became
69 II, 5. 7. 3| incidence rates of RRT for diabetic and hypertensive ESRD (Stengel
70 II, 5. 7. 3| incidence rates of RRT for diabetic and hypertensive ESRD (Stengel
71 II, 5. 7. 4| incidence rates of RRT for diabetic ESRD and differences in
72 II, 8. 2. 2| Table 8.3). Glaucoma and diabetic retinopathy are also significant
73 II, 8. 2. 2| Table 8.3). Glaucoma and diabetic retinopathy are also significant
74 II, 9. 3. 1| stress and hypertension in diabetic women (European Heart Network,
